{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:18:58Z","timestamp":1648808338785},"reference-count":20,"publisher":"Akademiai Kiado Zrt.","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Diabetes mellitus as comorbidity is present in 20\u201325% of patients suffering from high blood pressure. Because simultaneous presence of these two diseases results in a significant increase of cardiovascular risk, various guidelines focus greatly on the anti-hyperintensive treatment of patients with diabetes. Combined drug therapy is usually required to achieve the blood pressure target value of &lt;140\/85 mmHg defined for patients with diabetes, which must be based on angiotensin converting enzyme-inhibitors or angiotensin receptor blockers. These can be\/must be combined with low dose, primarily thiazid-like diuretics, calcium channel blockers with neutral metabolic effect, and further options include the addition of beta blockers, imidazolin-l-receptor antagonists, or alpha-1-adrenoreceptor blockers. Evidence-based guidelines are obviously present in local practice. Although most of the patients receive angiotensin converting enzyme-inhibitor+indapamid or angiotensin converting enzyme-inhibitor+calcium channel blocker combined therapy with favorable metabolic effects, yet the use of angiotensin converting enzyme-inhibitors containing hidrochlorotiazide having diabetogenic potencial, and angiotensin receptor blocker fixed combinations is still widespread. Similarly, interesting therapeutic practice can be observed with the use of less differentiated beta blockers, where the 3rd generation carvediolol and nebivolol are still in minority. Orv. Hetil., 2014, 155(43), 1695\u20131700.<\/jats:p>","DOI":"10.1556\/oh.2014.29988","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T01:01:16Z","timestamp":1413766876000},"page":"1695-1700","source":"Crossref","is-referenced-by-count":0,"title":["Domestic practice of antihypertensive treatment of diabetic hypertensive patients"],"prefix":"10.1556","volume":"155","author":[{"given":"Veronika","family":"Szentes","sequence":"first","affiliation":[{"name":"Petz Alad\u00e1r Megyei Oktat\u00f3 K\u00f3rh\u00e1z Kardiol\u00f3giai Oszt\u00e1ly Gy\u0151r Vasv\u00e1ri P\u00e1l u. 2\u20134. 9024"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Megyei Oktat\u00f3 K\u00f3rh\u00e1z Kardiol\u00f3giai Oszt\u00e1ly Gy\u0151r Vasv\u00e1ri P\u00e1l u. 2\u20134. 9024"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Megyei Oktat\u00f3 K\u00f3rh\u00e1z Kardiol\u00f3giai Oszt\u00e1ly Gy\u0151r Vasv\u00e1ri P\u00e1l u. 2\u20134. 9024"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","unstructured":"<i>K\u00e9kes, E., Kiss, I., Schanberg, Zs., et al.:<\/i> Annual experiences of the \u201eLong live below 140\/90 mmHg!\u201d movement. Characterization of the Hungarian population. [\u201e\u00c9ljen 140\/90 Hgmm alatt!\u201d mozgalom egy\u00e9ves tapasztalatai. A magyar popul\u00e1ci\u00f3 jellemz\u00e9se.] Hippocrates, 2006, <i>8<\/i>(3), 128\u2013132. [Hungarian]"},{"key":"2","unstructured":"<i>Kiss, I., K\u00e9kes, E., Schanberg, Zs., et al.:<\/i> \u201eLong live below 140\/90 mmHg!\u201d National movement of the Hungarian Society of Hypertension for the suppression of hypertension\u2019s prevalence. [\u201e\u00c9ljen 140\/90 Hgmm alatt!\u201d A Magyar Hypertonia T\u00e1rsas\u00e1g orsz\u00e1gos mozgalma a hypertoniabetegs\u00e9g el\u0151fordul\u00e1s\u00e1nak viszszaszor\u00edt\u00e1s\u00e1\u00e9rt.] Medicus Anonymus, 2010, <i>3\u20134,<\/i> 27\u201328. [Hungarian]"},{"key":"3","unstructured":"<i>Kiss, I.<\/i> (ed.): Professional and organizational guidelines of the Hungarian Society of Hypertension: guidelines for adult and pediatric treatment of hypertension. Commitment and recommendation of the Hungarian Society of Hypertension. 9th edition [Magyar Hypertonia T\u00e1rsas\u00e1g szakmai \u00e9s szervezeti ir\u00e1nyelvei. A hypertoniabetegs\u00e9g feln\u0151ttkori \u00e9s gyermekkori kezel\u00e9s\u00e9nek szakmai \u00e9s szervezeti ir\u00e1nyelvei. A Magyar Hypertonia T\u00e1rsas\u00e1g \u00e1ll\u00e1sfoglal\u00e1sa \u00e9s aj\u00e1nl\u00e1sa. 9. kiad\u00e1s] Hypertonia \u00e9s Nephrologia, 2009, <i>13<\/i>(82), 81\u2013168. [Hungarian]"},{"key":"4","unstructured":"<i>G\u00e1l, Zs., Ger\u0151, L., Hidv\u00e9gi T., et al.<\/i><i>(eds.):<\/i> Guidelines of the Hungarian Diabetes Association: The diagnosis of diabetes mellitus, treatment and care of adult patients with diabetes. [A Magyar Diabetes T\u00e1rsas\u00e1g szakmai ir\u00e1nyelve: A diabetes mellitus k\u00f3rism\u00e9z\u00e9se, a cukorbetegek kezel\u00e9se \u00e9s gondoz\u00e1sa a feln\u0151ttkorban.] Diabetologia Hungarica, 2014, <i>22<\/i>(Suppl.1). [Hungarian]"},{"key":"5","unstructured":"<i>\u00c1brah\u00e1m, Gy., Habony, N., Lantos, \u00c9.:<\/i> The appearance of recommendations in the local practices of treating hypetension. The initial results of the HERCULES (Hungarian HypERtensive Patients\u2019 Treatment in line with CUrrent Therapeutical GuideLine Study) study. [Az aj\u00e1nl\u00e1sok \u00e9rv\u00e9nyes\u00fcl\u00e9se hazai a magasv\u00e9rnyom\u00e1s-betegek kezel\u00e9s\u00e9ben: a HERCULES vizsg\u00e1lat els\u0151 eredm\u00e9nyei.] H\u00e1ziorvos Tov\u00e1bbk\u00e9pz\u0151 Szemle, 2012, <i>17<\/i>(7), 420\u2013425. [Hungarian]"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>The ACCORD Study Group, Cushman, W. C., Evans, G. W., Byington, R. P., et al.:<\/i> Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med., 2010, <i>362<\/i>(17), 1575\u20131585.","DOI":"10.1056\/NEJMoa1001286"},{"key":"7","doi-asserted-by":"crossref","unstructured":"<i>Mancia, G., Fagard, R., Narkiewicz, K., et. al.:<\/i> 2013 ESH\/ESC guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013, <i>31<\/i>(7), 1281\u20131357.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"8","unstructured":"National Institute for Health and Clinical Excellence (NICE) clinical guideline 127: Hypertension clinical management of primary hypertension in adults. <a href=\"http:\/\/www.nice.org.uk\/guidance\/CG127\/NICEGuidance\">http:\/\/www.nice.org.uk\/guidance\/CG127\/NICEGuidance<\/a>"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Bakris, G., Molitch, M., Hewkin, A., et al.:<\/i> Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care, 2006, <i>29<\/i>(12), 2592\u20132597.","DOI":"10.2337\/dc06-1373"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Bakris, G., Molitch, M., Zhou, Q., et al.:<\/i> Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET Study. J. Cardiometab. Syndr., 2008, <i>3<\/i>(1), 18\u201325.","DOI":"10.1111\/j.1559-4572.2008.07819.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Fox, K. M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators:<\/i> Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, <i>362<\/i>(9386), 782\u2013788.","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>PROGRESS Collaborative Group:<\/i> Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, <i>358<\/i>(9287), 1033\u20131041.","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Dahl\u00f6f, B., Sever, P. S., Poulter, N. R., et al., ASCOT investigators:<\/i> Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, <i>366<\/i>(9489), 895\u2013906.","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"<i>Patel, A.,<\/i> ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007, <i>370<\/i>(9590), 829\u2013840.","DOI":"10.1016\/S0140-6736(07)61303-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Beckett, N. S., Peters, R., Fletcher, A. E., et al.,<\/i> for the HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med., 2008, <i>358<\/i>(18), 1887\u20131898.","DOI":"10.1056\/NEJMoa0801369"},{"key":"16","doi-asserted-by":"crossref","unstructured":"<i>The ONTARGET Investigators, Yusuf, S., Teo, K. K., Pogue, J., et al.:<\/i> Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, <i>358<\/i>(15), 1547\u20131559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"17","doi-asserted-by":"crossref","unstructured":"<i>D\u00e9zsi, C. A.:<\/i> The role of ramipril in the therapy of diabetic nephropathy. [A ramipril helye a diabeteses nephropathia ter\u00e1pi\u00e1j\u00e1ban.] Orv. Hetil., 2014, <i>155<\/i>(7), 263\u2013269. [Hungarian]","DOI":"10.1556\/OH.2014.29827"},{"key":"18","unstructured":"<i>Fi, Zs., D\u00e9zsi, C. A.:<\/i> The significance of the metabolically neutral antihypertensive treatment in everyday medical practice. [Az anyagcsere-semleges hat\u00e1s\u00fa antihipertenz\u00edv kezel\u00e9s jelent\u0151s\u00e9ge a mindennapi orvosi gyakorlatban.] Lege Artis Medicin\u00e6, 2010, <i>20<\/i>(5), 305\u2013307. [Hungarian]"},{"key":"19","unstructured":"<i>D\u00e9zsi, C. A.:<\/i> On what criteria should we choose the beta-blocker? [Mi alapj\u00e1n v\u00e1lasszunk b\u00e9ta-blokkol\u00f3t?] Cardiologia Hungarica, 2012, <i>42<\/i>(5), 317\u2013321. [Hungarian]"},{"key":"20","unstructured":"<i>Moser, Gy., D\u00e9zsi, C. A.:<\/i> Problems and solutions in switching from a selective \u03b2-blocker to carvedilol. [Probl\u00e9m\u00e1k \u00e9s megold\u00e1sok szelekt\u00edv b\u00e9ta-blokkol\u00f3r\u00f3l carvedilolra t\u00f6rt\u00e9n\u0151 ter\u00e1piav\u00e1lt\u00e1s kapcs\u00e1n.] Cardiologia Hungarica, 2006, <i>36<\/i>(4), 283\u2013288. [Hungarian]"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2014.29988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:56:05Z","timestamp":1590141365000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2014.29988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":20,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1556\/OH.2014.29988"],"URL":"https:\/\/doi.org\/10.1556\/oh.2014.29988","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}